8 Comments
User's avatar
Guillermou's avatar

Excellent essay👍🏆🙏🏼. As a commenter on Dr. Marik’s Substack, I believe this reflection opens a discussion that deserves to extend well beyond the risks associated with biopsies. We can move toward less invasive diagnostic methods—such as liquid biopsy (ctDNA)—and surgical techniques that minimize tumor manipulation, including laparoscopy, thoracoscopy, or robotic surgery.

I also believe it is crucial to pay greater attention to the recovery period. Inflammation, surgical stress, and transient alterations in the immune response may influence the progression of the disease and the risk of recurrence. In this regard, points 4 and 5 of Dr. Paul Marik’s metabolic approach—which focus on the tumor microenvironment and immune surveillance—are particularly compelling.

In terms of cancer patient care, we must broaden our perspective: the goal is not merely to eliminate the tumor, but also to preserve healthy tissue as much as possible, facilitate a robust recovery, and gain a deeper understanding of the mechanisms that allow tumor cells to survive, regenerate, and spread. Cancer stem cells pose a serious risk for metastasis—a risk that, as we know, chemotherapy fails to eliminate. Preventing recurrence deserves as much attention as the treatment itself. Furthermore, beyond medical procedures, we must not overlook daily preventive measures: a healthy diet, regular physical exercise, and sound lifestyle habits are essential tools for nurturing our "metabolic terrain," maintaining inflammatory balance, and supporting immune health. It is not just about fighting disease; it is about creating the best possible conditions to preserve health.❤️

Scientific references:

1. Liquid Biopsy (2025): The potential of circulating tumor DNA (ctDNA) as a less invasive alternative for studying and monitoring cancer.

https://pmc.ncbi.nlm.nih.gov/articles/PMC12207651/. 2. Perioperative Immunosuppressive Factors during Cancer Surgery (2024): the influence of surgical stress, inflammation, and immunity during the perioperative period.

https://pmc.ncbi.nlm.nih.gov/articles/PMC11240822/.

3. Perioperative Anesthesia Management and Immunosuppression (2025): the relationship between anesthesia, the immune response, and potential tumor recurrence.

https://pmc.ncbi.nlm.nih.gov/articles/PMC12380853/

4. Tumor Seeding Across Specialties (2024): a systematic review regarding the potential dissemination of tumor cells during biopsies and medical procedures.

https://pmc.ncbi.nlm.nih.gov/articles/PMC11598697/.

5. The Five-Axis Metabolic Trap: Targeting Five Cancer Pathways at Once

Presents the five axes and a proposal to target metabolism, mitochondria, cancer stem cells, the cytoskeleton, the tumor microenvironment, and immunity. https://imahealth.org/the-metabolic-trap-targeting-five-cancer-pathways-at-once/

Tardigrade's avatar

This is tangential to today's article: I remember reading a paper, many years ago, that mammograms, because of the extreme squeezing, can cause leaking and subsequent proliferation of tumor cells.

The Color Of Air's avatar

Invading the body with needles is not normal. The medical mafia is never trying to find a cure for cancer. They try to invent new drugs that manage the agony and pretend to prolong or save lives. If allowed, the body can do the best curing it knows how. Unfortunately it cannot always supersede the destructive practices of modern medicine.

Guylaine's avatar

New thought from this essay, is no Biopsy if you are not considering surgery. if surgery is off the table so should the biopsy.

Guillermou's avatar

It is also essential that, following surgery, a comprehensive anatomopathological and molecular analysis of the resected tumor be performed. This information can help identify relevant biological characteristics and guide more precise follow-up. Liquid biopsy using ctDNA is a promising tool for monitoring potential minimal residual disease and detecting molecular signs of a relapse before it becomes visible on imaging tests. This is part of precision oncology: understanding the molecular characteristics of the tumor, personalizing treatment, and using tools such as liquid biopsy to monitor for potential residual disease and guide individualized follow-up.

ESMO – ctDNA and precision medicine (2026)

https://www.esmo.org/insights-by-esmo/all-news/ctdna-is-unlocking-new-clinical-opportunities-for-liquid-biopsy

Barbara Charis's avatar

It is difficult to believe that so many totally accept information from those, because they have the letters DR. before their names. Hippocrates said that there are many doctors, but very few physicians who worked from the soul and were into the Art of Healing.

I have no desire to permit a doctor to touch my body...I've no desire to even enter a doctor's office. In my opinion, those who prescribe drugs and vaccines are ignorant about how the human body works. I have no desire for them to do their practicing on me.

Don's avatar

Never again!

Clark Baker's avatar

I read the pamphlet, and the page it was taken from.

I'd keep the survey. You put the growth-model account on the page before you leave it, which is more than most essays in this register manage. A reader can check Silva, Nie, the Hopkins series, and Volanis. A liver biopsy goes in through the skin. No gut flora is on that needle, and the tract still seeds. That one fact separates the infection problem from the deposit problem. A transperineal route is the better choice against sepsis. It does not answer the second question.

Where the pamphlet loses the reader is the receipts page. Two different measurements have been set in one column, and a person who has not opened the papers will take them for the same event. Loughran and Keeling found tumor cells along the track in 22% of excision specimens. Hoorntje found displacement in half of the tracks that were still visible the same day. Those are cells seen at surgery. Nie's 0.62%, across 13,959 biopsies, and Silva's 2.7%, are clinical seeding, a mass a clinician could point to later. The abdominal-wall lump that appeared 15 years after a liver biopsy is that second thing. It is not the 22%. Stigliano's 1.17%, which your own note says pools biopsy and ablation across 4,609 cases, is the figure that would have warned a reader the column was mixed. It is the figure left off the card. The 9.4% sepsis line cites your February essay. It does not cite a paper.

The delay argument then turns the finding around. You report that displacement falls as the weeks between biopsy and excision lengthen. If the mainstream reading of that fall is that the displaced cells die off, waiting is the condition under which less of the deposit is still there. Your reading says those weeks are a leak. I can follow either reading. I cannot follow the sentence in which both of them require the surgery to be arranged before the needle goes in. That sentence is not in the interval data.

A mass that appears 15 years along an old needle path does not break the growth model. Oncology already has a name for a cell that sits and later grows. The scatter from one series to the next, zero in one hospital and 7.77% in another, sits inside that model as well, because the tissue the needle enters decides whether a deposit takes. The genome-atlas passage is a different argument, brought in from another room. Aneuploidy, and a crowd of passenger mutations, is what clonal evolution looks like under the microscope. "Cells falling apart" is a sentence in the pamphlet. It is not a result the paper reports.

After the journals stop, the chemistry arrives from somewhere else. Collapsed cell water, zeta potential, seed oils, iron, copper, particles photographed in injectable products: the seeding tables do not select any of that. The scene that opens the essay and the scene that closes it are one observation, from a webinar on 11 November 2026. The pamphlet does not include the histology. The published case reports are the stronger evidence, and you already cited them.

What I would keep is smaller than the pamphlet, and it does not need the second half. A biopsy is a puncture, and the journals have a deposit rate for it. If the plan is already to cut the mass out, the needle and the operation are one decision, and a delay of weeks belongs in the words said before consent. Imaging will not stand in for a pathology report when the treatment still depends on what the mass is. That last claim is true only for a reader who has already accepted the model. It is not true for anyone else.